コンテンツへスキップ
Merck
  • Contralateral eye comparison of descemet membrane endothelial keratoplasty and descemet stripping automated endothelial keratoplasty.

Contralateral eye comparison of descemet membrane endothelial keratoplasty and descemet stripping automated endothelial keratoplasty.

American journal of ophthalmology (2014-12-03)
Yakov Goldich, Mahmood Showail, Noa Avni-Zauberman, Mauricio Perez, Randall Ulate, Uri Elbaz, David S Rootman
要旨

To compare objective and subjective outcomes after Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK) in the fellow eye of the same patients. Single-center, retrospective case series. Seventeen patients with bilateral Fuchs endothelial dystrophy who underwent DSAEK earlier in 1 eye, and later underwent DMEK in the contralateral eye, composed study population. A chart review was completed to obtain follow-up data for at least 6 months after each surgery. Outcome measures included best spectacle-corrected visual acuity (BSCVA) and endothelial cell density (ECD). Subjective questionnaires were used to assess patients' satisfaction. Preoperative BSCVA (logMAR) was similar in both groups, 0.66 ± 0.4 in DMEK and 0.59 ± 0.4 in DSAEK (P = .6). The DMEK group showed better BSCVA than the DSAEK group at the 6-month time point (0.25 ± 0.1 and 0.39 ± 0.1, for DMEK and DSAEK, respectively, P = .02). Preoperative ECD (cells/mm(2)) was similar in both groups (2647 ± 249 and 2768 ± 404, P = .3) in DMEK and DSAEK, respectively. There was statistically significant difference found in ECD at 6 months (2227 ± 565 for DMEK and 1780 ± 433 for DSAEK, P = .049). Subjective level of average satisfaction after DMEK was 6 and after DSAEK was 4.87 ± 1.19 (P = .002). DMEK provided better visual outcome and lower endothelial cell loss than DSAEK and a higher level of patient satisfaction when assessed at 6 months after surgery. Our results comparing the 2 procedures in the same patients support the benefits of DMEK, and suggest the need for long-term studies observing this new surgical procedure.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
デキサメタゾン 21-リン酸 二ナトリウム塩, ≥98%
Sigma-Aldrich
トブラマイシン, Aminoglycoside antibiotic
USP
トブラマイシン, United States Pharmacopeia (USP) Reference Standard
Supelco
トブラマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
デキサメタゾン 21-リン酸 二ナトリウム塩, European Pharmacopoeia (EP) Reference Standard
トブラマイシン, European Pharmacopoeia (EP) Reference Standard
デキサメタゾン 21-リン酸 二ナトリウム塩, European Pharmacopoeia (EP) Reference Standard
システム適合性用シクロペントレート, European Pharmacopoeia (EP) Reference Standard
シクロペントラート 塩酸塩, European Pharmacopoeia (EP) Reference Standard